NCT00623701

Brief Summary

Efficacy and Safety from a high-dosed sublingual grass pollen preparation

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
126

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Mar 2008

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 19, 2008

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 26, 2008

Completed
4 days until next milestone

Study Start

First participant enrolled

March 1, 2008

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2011

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2012

Completed
Last Updated

November 8, 2013

Status Verified

November 1, 2013

Enrollment Period

3.6 years

First QC Date

February 19, 2008

Last Update Submit

November 7, 2013

Conditions

Keywords

sublingual grass pollen preparationIgE-mediated Allergic Disease attributed to grass pollen

Outcome Measures

Primary Outcomes (1)

  • Symptom and Medication Score

    Grass pollen season 2009

Study Arms (2)

1

PLACEBO COMPARATOR

sublingual placebo preparation

Biological: Allerslit forte

2

EXPERIMENTAL

Sublingual preparation, 40 micro grams Phl p 5 maintenance dose

Biological: Allerslit forte

Interventions

Allerslit forteBIOLOGICAL

sublingual placebo preparation, daily

1

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Allergic rhinoconjunctivitis attributable to grass pollen
  • Positive SPT
  • Positive EAST
  • Positive provocation Test

You may not qualify if:

  • Serious chronic disease
  • other perennial allergies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Prof. Kristian Reich, MD

Hamburg, 20354, Germany

Location

Related Links

MeSH Terms

Conditions

HypersensitivityRhinitisConjunctivitis

Interventions

AllerSlit forte

Condition Hierarchy (Ancestors)

Immune System DiseasesRespiratory Tract InfectionsInfectionsNose DiseasesRespiratory Tract DiseasesOtorhinolaryngologic DiseasesConjunctival DiseasesEye Diseases

Study Officials

  • Kristian Reich, Professor

    not affiliated

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 19, 2008

First Posted

February 26, 2008

Study Start

March 1, 2008

Primary Completion

October 1, 2011

Study Completion

October 1, 2012

Last Updated

November 8, 2013

Record last verified: 2013-11

Locations